Back to search results

Empagliflozin for Pulmonary Arterial Hypertension

This study is testing if a drug called empagliflozin (10 mg once daily) can improve the function of the right side of the heart in people with pulmonary arterial hypertension (PAH). PAH is a condition where blood pressure in the arteries of the lungs is too high. You might be able to join if you are 18 or older, can read and write English, and are willing to follow all study procedures. The main goal is to see how much empagliflozin changes the pumping ability of your right heart over 24 weeks, as measured by a special MRI scan. This study is currently recruiting 78 participants, but its exact status is unclear.

Study design
This is a randomized, triple-masked study comparing empagliflozin to a placebo. About 78 participants will be randomly assigned to receive either empagliflozin or a matching placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at 24 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06992440

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

Recruiting
PHASE2Ages 18+InterventionalTreatment
Gustavo A Heresi, MD, MS
~78 participants
Updated 2026-08-13 on ClinicalTrials.gov
What's tested:Empagliflozin 10 MGPlacebo

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in RV ejection fraction measured by CMR
Measured over 24 weeks

Conditions

Pulmonary Arterial Hypertension

Explore related trials

Pulmonary Arterial Hypertension

NCT06992440

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cleveland Clinic

    Cleveland, Ohiostudy coordinator listed

    Recruiting

  • The Johns Hopkins Hospital

    Baltimore, Marylandstudy coordinator listed

    Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennesseestudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Gustavo Heresi, MD · PRINCIPAL_INVESTIGATOR · The Cleveland Clinic

Who to contact

Gustavo Heresi, MD
[email protected]
216 636-5327
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

In order to be eligible to participate in this study, an individual must meet all the following criteria:

Exclusion

An individual who meets any of the following criteria will be excluded from participation in this study:

What this trial measures

  • Change in RV ejection fraction measured by CMR24 weeks

    RV ejection fraction measured by CMR before and after treatment